Virginia 2022 Regular Session

Virginia Senate Bill SB772

Introduced
1/21/22  
Refer
1/21/22  
Report Pass
2/10/22  
Engrossed
2/14/22  

Caption

Cannabis; definitions, dispensing products, patient registration.

Impact

With the passage of SB772, state laws surrounding medical cannabis are expected to become more comprehensive. The bill provides a framework for the registration of patients and practitioners involved in the medical cannabis process. One significant impact includes the establishment of safety regulations and health standards for cannabis production and dispensing. It brings a level of legitimacy and safety to what has historically been an ambiguous area of law, potentially enhancing the quality of care for patients requiring cannabis for treatment.

Summary

SB772 focuses on the legal framework for the medical use of cannabis in Virginia, detailing the definitions of cannabis products, the certification process for patients, and the guidelines governing the dispensing of these products. The bill aims to provide clarity and structure for physicians and patients interested in accessing cannabis for therapeutic purposes while regulating the production and distribution of cannabis products by licensed pharmaceutical processors and dispensing facilities. It embraces a more defined role for medical practitioners in the issuance of certifications for cannabis use, thereby facilitating better patient access to medicinal cannabis.

Sentiment

Overall, the sentiment around SB772 seems cautiously optimistic among supporters, who believe that the bill will improve accessibility to medical cannabis for patients. Advocacy groups and medical professionals emphasized its necessity in providing effective treatments for qualifying conditions. However, there remains a contingent of skeptics expressing concerns about the potential for misuse and the implications of integrating cannabis into mainstream medical practice, raising questions about the ethical and health ramifications of its wider use.

Contention

Notable points of contention regarding SB772 revolve around its implementation and the regulatory oversight of cannabis dispensing. Critics question whether the proposed regulations adequately address concerns about patient safety and product quality. There are also discussions on the impact of the bill on existing laws governing controlled substances. As medical cannabis grows more prevalent, the balance between accessibility for patients and the need for stringent controls remains a pivotal topic of debate among lawmakers and constituents.

Companion Bills

No companion bills found.

Previously Filed As

VA HB1989

Medical cannabis program; changes requirements for product labels, dispensing cannabis products.

VA HB2775

Hemp product; clarifies definition.

VA AB384

Cannabis and cannabis products: animals: veterinary medicine.

VA AB1885

Cannabis and cannabis products: animals: veterinary medicine.

VA HB1164

The definition of cannabinoid edible products.

VA SB00970

An Act Concerning Cannabinoids, Hemp And Hemp Products.

VA SB627

Cannabis and cannabis products: medicinal use on an animal: veterinary medicine.

VA SB292

Prohibiting the transfer of hemp-derived cannabinoid products to any person under the age of 21, establishing packaging and labeling requirements for such products and amending the definition of industrial hemp and hemp products.

VA SB555

Creating the medical cannabis pilot program act to establish the medical cannabis pilot program for limited cultivation, processing and dispensing of medical cannabis and medical cannabis products.

VA SB1715

Hemp-derived manufactured impairing cannabinoids

Similar Bills

No similar bills found.